gssg glutathione oxidized Oncology Letters Analysis of GSH and GSSG

The Phase 2/3 LIFT-AD trial (NCT04488419), evaluating once-daily subcutaneous fosgonimeton 40 mg versus placebo in 312 participants with mild-to-moderate Alzheimers disease over 26 weeks, failed its primary endpoint (Global Statistical Test composite of ADAS-Cog11 and ADCS-ADL23) and its key secondary endpoints when results were announced in September 2024

For most healthy people, a balanced diet containing animal products provides sufficient B12

Therapeutic Benefits of NAD+ When you increase your levels of NAD+, your cells are able to produce more energy, your DNAis repaired, your good genes are turned on, it protects the brain, and many other health functions are improved

On a practical level, the population diversity in bioactivation and detoxification abilities could effectively obscure any threshold